Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $50.0M buybacks = $50.0M returned on $105.1M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 4%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.85B 100.0% | $1.72B 100.0% | $1.56B 100.0% | $1.33B 100.0% | $1.22B 100.0% | $1.07B 100.0% | $1.26B 100.0% | $1.22B 100.0% | $1.14B 100.0% | $1.08B 100.0% |
| Cost of Revenue | $1.35B 73.0% | $1.26B 73.3% | $1.15B 73.7% | $985.5M 74.0% | $884.1M 72.4% | $787.7M 73.4% | $903.1M 71.8% | $852.3M 70.2% | $782.1M 68.8% | $737.8M 68.6% |
| Gross Profit | $500.4M 27.0% | $459.0M 26.7% | $409.9M 26.3% | $345.8M 26.0% | $337.0M 27.6% | $285.7M 26.6% | $355.0M 28.2% | $362.7M 29.8% | $354.0M 31.2% | $337.7M 31.4% |
| Selling, General & Admin | $211.7M 11.4% | $185.2M 10.8% | $173.2M 11.1% | $158.1M 11.9% | $141.4M 11.6% | $109.0M 10.2% | $138.7M 11.0% | $142.4M 11.7% | $143.1M 12.6% | $136.4M 12.7% |
| Total Operating Expenses | $279.1M 15.1% | $250.8M 14.6% | $246.6M 15.8% | $233.1M 17.5% | $201.3M 16.5% | $165.1M 15.4% | $197.4M 15.7% | $207.1M 17.0% | $228.4M 20.1% | $244.8M 22.8% |
| Operating Income | $221.3M 11.9% | $208.2M 12.1% | $163.3M 10.5% | $112.7M 8.5% | $135.7M 11.1% | $120.6M 11.2% | $157.6M 12.5% | $155.6M 12.8% | $125.6M 11.1% | $92.9M 8.6% |
| Interest Expense | $43.2M 2.3% | $56.4M 3.3% | $53.4M 3.4% | $38.6M 2.9% | $31.6M 2.6% | $38.2M 3.6% | $52.5M 4.2% | $99.3M 8.2% | $64.0M 5.6% | $68.3M 6.4% |
| Other Income (Expense), net | -$53.2M -2.9% | -$3.5M -0.2% | -$975K -0.1% | $899K 0.1% | $123K 0.0% | -$1.5M -0.1% | $578K 0.0% | -$752K -0.1% | -$10.9M -1.0% | $4.4M 0.4% |
| Pretax Income | $125.4M 6.8% | $147.6M 8.6% | $105.4M 6.8% | $68.7M 5.2% | $101.1M 8.3% | $86.2M 8.0% | $105.2M 8.4% | $61.1M 5.0% | $49.3M 4.3% | $28.2M 2.6% |
| Income Tax Expense | $22.6M 1.2% | $26.5M 1.5% | $16.2M 1.0% | $8.9M 0.7% | $8.0M 0.7% | $8.9M 0.8% | $14.0M 1.1% | $14.1M 1.2% | -$37.8M -3.3% | $3.3M 0.3% |
| Net Income | $102.8M 5.5% | $119.9M 7.0% | $90.7M 5.8% | $66.4M 5.0% | $96.8M 7.9% | $77.3M 7.2% | $96.3M 7.7% | $168.0M 13.8% | $66.7M 5.9% | $6.0M 0.6% |
| Per Share | ||||||||||
| EPS (Basic) | $2.96 | $3.57 | $2.72 | $2.00 | $2.93 | $2.35 | $2.95 | $5.23 | $2.12 | $0.19 |
| EPS (Diluted) | $2.89 | $3.36 | $2.69 | $1.99 | $2.91 | $2.33 | $2.92 | $5.15 | $2.08 | $0.19 |
| Weighted Avg Shares (Basic) | 34.7M | 33.6M | 33.3M | 33.1M | 33.0M | 32.8M | 32.6M | 32.1M | 31.4M | 30.8M |
| Weighted Avg Shares (Diluted) | 35.6M | 35.6M | 33.8M | 33.4M | 33.3M | 33.1M | 33.0M | 32.6M | 32.1M | 31.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $17.2M (at 2025-12-31) covers the $0 due within a year 17161000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2026-07-03 (10-Q). The cash figure is from 2025-12-31, so the two are not the same balance-sheet date — the schedule has not been refiled since.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~3.6% on $1.19B of debt.
Cash of $17.2M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 3 positive fiscal years (FY2023, FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $126.59 today, the market must believe free cash flow compounds 17.4%/yr for a decade (off $88.4M on the 3-yr avg basis).
On the basis ($64.7M) the requirement is 21.5%/yr. Shares issued to employees are added back in operating cash flow, so this basis treats them as free.
The market's 17.4% is more optimistic than its 9-yr track record.
Default is 7.8% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.03B shares (market data) · net debt $1.17B
mean 20.1% · volatility σ 52% · implied rate exceeded in 4/9 yrs
Central path = implied 17.4%/yr growth; shaded band = ±1σ (52%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Ranked against 26 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BAX | $12.1B | — | 29.2× | 1.1× | 5.7% | 30.1% | -8.5% | -15.6% | -6.1% | 11.1× | 197 |
| GMED | $11.1B | 21.1× | 14.0× | 3.8× | 16.7% | 67.4% | 18.3% | 11.8% | 11.8% | -0.7× | 146 |
| ALGN | $10.9B | 27.2× | 12.5× | 2.7× | 0.9% | 67.2% | 10.2% | 10.1% | 10.1% | -1.4× | 152 |
| PODD | $10.6B | 43.8× | 18.8× | 3.9× | 30.7% | 71.6% | 9.1% | 16.3% | 16.1% | 0.0× | 164 |
| MSA | $6.9B | 25.3× | 16.5× | 3.7× | 3.7% | 46.5% | 14.9% | 20.4% | 14.3% | 0.9× | 104 |
| TFX | $6.0B | — | 47.3× | 3.0× | 17.2% | 56.2% | -45.4% | -29.0% | -15.7% | 13.0× | 73 |
| MMSI | $5.6B | 43.9× | 19.1× | 3.7× | 11.8% | 48.7% | 8.5% | 8.1% | 5.5% | 0.9× | 94 |
| HAE | $5.5B | 58.4× | 29.5× | 4.1× | -2.0% | 59.0% | 7.3% | 12.2% | 4.8% | 4.5× | 58 |
| MMED | $5.4B | — | — | 1.8× | 14.3% | 54.2% | -10.7% | -9.2% | -9.2% | — | — |
| HTFL | $5.3B | — | — | 29.9× | 39.9% | 76.8% | -66.3% | -38.8% | -38.8% | — | 36 |
| LIVN | $4.5B | — | 18.4× | 3.2× | 10.7% | 67.7% | -17.5% | -20.2% | -15.4% | -1.1× | 57 |
| ITGR | $4.3B | 43.8× | 15.5× | 2.3× | 8.0% | 27.0% | 5.5% | 5.9% | 3.5% | 3.3× | 70 |
| ICUI | $4.2B | — | 22.6× | 1.9× | -6.3% | 36.8% | 0.0% | 0.0% | 0.0% | 5.3× | 58 |
| IRTC | $4.2B | — | — | 5.6× | 26.2% | 70.6% | -6.0% | -29.2% | -29.2% | — | 51 |
| NVST | $4.0B | 87.9× | 12.6× | 1.4× | 8.3% | 54.7% | 1.7% | 1.5% | 1.0% | 0.7× | 76 |
| ATRC | $3.2B | — | — | 6.0× | 14.9% | 75.0% | -2.1% | -2.3% | -2.1% | — | 52 |
| AXGN | $3.0B | — | — | 13.2× | 20.2% | 74.3% | -7.0% | -12.2% | -8.9% | — | 38 |
| TMDX | $2.3B | 13.8× | 13.6× | 3.8× | 37.1% | 59.9% | 31.4% | 40.2% | 39.4% | -3.5× | 84 |
| UFPT | $2.3B | 33.5× | 21.4× | 3.8× | 19.5% | 28.3% | 11.3% | 16.1% | 12.2% | 1.0× | 69 |
| INSP | $2.1B | 14.6× | 30.1× | 2.3× | 13.6% | 85.4% | 15.9% | 18.6% | 18.6% | -1.6× | 56 |
| ESTA | $2.0B | — | — | 9.7× | 27.1% | 69.3% | -24.2% | -217% | -18.8% | — | 21 |
| BFLY | $2.0B | — | — | 20.5× | 19.0% | 46.9% | -79.0% | -39.3% | -39.3% | — | 47 |
| LMAT | $2.0B | 33.8× | 24.5× | 7.8× | 13.5% | 71.5% | 23.1% | 14.7% | 14.7% | -0.4× | 61 |
| XRAY | $1.9B | — | — | 0.5× | -3.0% | 50.0% | -16.3% | -44.7% | -16.3% | — | 77 |
| BLFS | $1.9B | — | — | 19.6× | 28.9% | 64.6% | -4.8% | -1.2% | -1.2% | — | 45 |
Peers = companies sharing ITGR's sector (Electromedical & Electrotherapeutic Apparatus) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-10-30
Where each multiple sits in its own 14-yr range · 84th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 6% against ROIC 4% — 2% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 70.2 | 71.8 | 73.4 | 72.4 | 74.0 | 73.7 | 73.3 | 73.0 |
| Gross Profit | 29.8 | 28.2 | 26.6 | 27.6 | 26.0 | 26.3 | 26.7 | 27.0 |
| SG&A | 11.7 | 11.0 | 10.2 | 11.6 | 11.9 | 11.1 | 10.8 | 11.4 |
| Operating Income | 12.8 | 12.5 | 11.2 | 11.1 | 8.5 | 10.5 | 12.1 | 11.9 |
| Income Tax | 1.2 | 1.1 | 0.8 | 0.7 | 0.7 | 1.0 | 1.5 | 1.2 |
| Net Income | 13.8 | 7.7 | 7.2 | 7.9 | 5.0 | 5.8 | 7.0 | 5.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ITGR: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Earns -1.79pts against its cost of capital — capital is being consumed, not created.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | 6.5% | 7.8% (today's — no rate published for this year) | -1.3pts |
| FY2020 | 5.0% | 7.8% (today's — no rate published for this year) | -2.8pts |
| FY2021 | 5.0% | 7.5% | -2.5pts |
| FY2022 | 3.9% | 8.5% | -4.6pts |
| FY2023 | 5.3% | 8.2% | -3.0pts |
| FY2024 | 6.4% | 8.7% | -2.3pts |
| FY2025 | 6.0% | 7.0% | -1.0pts |
| Now | 3.5% | 7.8% | -4.3pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 31.4% | 8.6% | 0.6% |
| FY2017 | 31.2% | 11.1% | 5.9% |
| FY2018 | 29.8% | 12.8% | 13.8% |
| FY2019 | 28.2% | 12.5% | 7.7% |
| FY2020 | 26.6% | 11.2% | 7.2% |
| FY2021 | 27.6% | 11.1% | 7.9% |
| FY2022 | 26.0% | 8.5% | 5.0% |
| FY2023 | 26.3% | 10.5% | 5.8% |
| FY2024 | 26.7% | 12.1% | 7.0% |
| FY2025 | 27.0% | 11.9% | 5.5% |
Leverage and buybacks account for 2 points of the 6% return on equity in FY2025. The business earns 4% on the capital it employs; the rest is balance sheet.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
$1.1B of goodwill — 36% of invested capital. The gap is what was paid above the fair value of what was bought; it is real capital shareholders provided, so neither bar is the whole answer.
ROIC ex-goodwill is 9.4% against 6.0% reported — the return is earned on a capital base inflated by what was paid for acquisitions, not by the operating business alone.
Converts 0.84x of reported profit into cash — adequate, without much margin.
Reported free cash flow is $105M; after share-based compensation it is $82M. The difference is a real cost that the cash flow statement adds back.
Covers interest 3.6x under stress — adequate, without much room.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | 5.12x |
| 5% | 4.87x |
| 10% | 4.61x |
| 15% | 4.35x |
| 20% | 4.10x |
| 25% | 3.84x |
| 30% | 3.58x |
| 35% | 3.33x |
| 40% | 3.07x |
| 45% | 2.82x |
| 50% | 2.56x |
| 55% | 2.30x |
| 60% | 2.05x |
Ladder as of 2026-07-03 (10-Q); cash from the 2025-12-31 balance sheet; FCF from FY2025.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
Coverage is comfortable at 5.1x today but falls to 3.6x after a 30% EBITDA decline — the cushion is earnings, not liquidity.
At $126.52, free cash flow must compound 17.67%/yr for 10 years. It has done -1.79%/yr over 6 years.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | 14.8% | 17.7% |
| FY2021 | −23.3% | 17.7% |
| FY2022 | −59.6% | 17.7% |
| FY2023 | 44.7% | 17.7% |
| FY2024 | 65.7% | 17.7% |
| FY2025 | 5.3% | 17.7% |
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
The implied rate has been matched or beaten in 2 of the last 6 years.
| Step | Amount | Running total |
|---|---|---|
| Net income | $103M | $103M |
| Share-based comp | $23M | $126M |
| Other non-cash & working capital | $70M | $196M |
| Operating cash flow | $196M | $196M |
| Capex | −$91M | $105M |
| Free cash flow | $105M | $105M |
| FCF after SBC | $82M | $82M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | -14.7% | -18.6% | -4.0 points |
| FY2021 | 13.8% | 16.7% | 3.0 points |
| FY2022 | 9.0% | 23.1% | 14.0 points |
| FY2023 | 16.9% | 3.1% | -13.8 points |
| FY2024 | 10.3% | 6.0% | -4.3 points |
| FY2025 | 8.0% | 41.1% | 33.1 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 55.7 days | 67.6 days | 26.3 days | 97 days |
| FY2020 | 53.1 days | 69.2 days | 23.9 days | 98.4 days |
| FY2021 | 54.5 days | 64.3 days | 31.7 days | 87 days |
| FY2022 | 61.5 days | 77.3 days | 41 days | 97.8 days |
| FY2023 | 54.3 days | 73 days | 37.7 days | 89.6 days |
| FY2024 | 52.2 days | 71.7 days | 29.5 days | 94.4 days |
| FY2025 | 68.1 days | 68.4 days | 30.5 days | 106.1 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -2.9 percent |
| FY2020 | -4.4 percent |
| FY2021 | -2.3 percent |
| FY2022 | -1.8 percent |
| FY2023 | -3.0 percent |
| FY2024 | -2.8 percent |
| FY2025 | -2.7 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Below the line for 2 consecutive years to the latest.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-24 | 3 co-filers President & CEO | Option exercise | 2,514 | — | — |
| 2026-10-24 | 3 co-filers President & CEO | Tax withholding | 990 | $126.54 | $125k |
| 2026-10-24 | 3 co-filers President & CEO | Option exercise | 2,514 | $0.00 | — |
| 2026-09-15 | 2 co-filers Chief Human Resources Officer | Open-market sale | 11,767 | $126.23 | $1.5m |
| 2026-09-14 | 2 co-filers Chief Human Resources Officer | Open-market sale | 19,773 | $126.25 | $2.5m |
| 2026-09-08 | Senn Andrew President, Growth & Innovation | Open-market sale | 9,408 | $126.30 | $1.2m |
| 2026-07-06 | 2 co-filers US - EVP, Operations | Grant | 892 | $0.00 | — |
| 2026-07-06 | 2 co-filers US - EVP, Operations | Grant | 4,532 | $0.00 | — |
| 2026-06-30 | 3 co-filers Chief Human Resources Officer | Option exercise | 6,120 | — | — |
| 2026-06-30 | 3 co-filers Chief Human Resources Officer | Tax withholding | 2,409 | $93.45 | $225k |
| 2026-06-30 | 3 co-filers Chief Human Resources Officer | Option exercise | 6,120 | $0.00 | — |
| 2026-06-29 | Harris John A President, Glob Ops & Manu Tec | Grant | 1,096 | $0.00 | — |
| 2026-05-20 | Hinrichs James F. Director | Grant | 1,967 | $0.00 | — |
| 2026-05-20 | Kapito Aaron Director | Grant | 1,967 | $0.00 | $0 |
| 2026-05-20 | Flanagan James Francis Director | Grant | 1,967 | $0.00 | $0 |
| 2026-05-20 | Capps Cheryl C Director | Grant | 1,967 | $0.00 | $0 |
| 2026-05-20 | Antrum Sheila Director | Grant | 1,967 | $0.00 | $0 |
| 2026-05-20 | Jeffers Alvin Tyrone Director | Grant | 1,967 | $0.00 | $0 |
| 2026-05-20 | Spence Donald J Director | Grant | 2,623 | $0.00 | — |
| 2026-05-20 | Passerini Filippo Director | Grant | 1,967 | $0.00 | $0 |
| 2026-05-20 | Maxwell Martin C Director | Grant | 1,967 | $0.00 | $0 |
| 2026-05-20 | Coyle Michael J Director | Grant | 1,967 | $0.00 | $0 |
| 2026-05-18 | Thomas Tommy P VP, Corporate Controller | Grant | 666 | $0.00 | — |
| 2026-05-15 | 5 co-filers President, CRM & Neuro | Option exercise | 491 | $0.00 | $0 |
| 2026-05-15 | 5 co-filers President, CRM & Neuro | Option exercise | 1,472 | $0.00 | $0 |
| 2026-05-15 | 5 co-filers President, CRM & Neuro | Tax withholding | 479 | $88.16 | $42k |
| 2026-05-15 | 5 co-filers President, CRM & Neuro | Option exercise | 491 | $0.00 | — |
| 2026-05-15 | 5 co-filers President, CRM & Neuro | Option exercise | 1,472 | $0.00 | — |
| 2026-05-08 | 3 co-filers EVP, Chief Financial Officer | Option exercise | 2,063 | $0.00 | $0 |
| 2026-05-08 | 3 co-filers EVP, Chief Financial Officer | Tax withholding | 503 | $88.12 | $44k |
| 2026-05-08 | 3 co-filers EVP, Chief Financial Officer | Option exercise | 2,063 | $0.00 | — |
| 2026-03-31 | 3 co-filers EVP, Global Ops and Manufactur | Option exercise | 3,837 | — | — |
| 2026-03-31 | 3 co-filers EVP, Global Ops and Manufactur | Tax withholding | 1,842 | $88.00 | $162k |
| 2026-03-31 | 3 co-filers EVP, Global Ops and Manufactur | Option exercise | 3,837 | $0.00 | — |
| 2026-03-24 | 5 co-filers SVP, Gen Counsel & Secretary | Option exercise | 1,777 | — | — |
| 2026-03-24 | 3 co-filers EVP, Qlty & Regulatory Affairs | Option exercise | 1,350 | — | — |
| 2026-03-24 | 3 co-filers EVP, Qlty & Regulatory Affairs | Tax withholding | 398 | $86.19 | $34k |
| 2026-03-24 | 5 co-filers SVP, Gen Counsel & Secretary | Option exercise | 1,706 | — | — |
| 2026-03-24 | 3 co-filers EVP, Qlty & Regulatory Affairs | Option exercise | 1,350 | $0.00 | — |
| 2026-03-24 | 5 co-filers SVP, Gen Counsel & Secretary | Tax withholding | 1,049 | $86.19 | $90k |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.